IGC Pharma, Inc. (IGC) - Form 10-K Summary
Business Context and Reporting Period
Company: IGC Pharma, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal Year Ended March 31, 2025
Business Focus: Clinical-stage pharmaceutical company focused on developing treatments for Alzheimer's disease (AD) and related neurodegenerative conditions. The Company operates as a single reportable segment (Life Sciences) following the cessation of its Infrastructure segment operations in Fiscal 2025.
Key Asset: IGC-AD1, a lead investigational drug candidate currently in Phase 2 clinical trials (CALMA study) targeting agitation in Alzheimer's dementia.
Key Financial Metrics (Fiscal 2025 vs. Fiscal 2024)
| Metric (in thousands) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Revenue | $1,271 | $1,345 | ($74) / -6% |
| Gross Profit | $619 | $733 | ($114) / -16% |
| Gross Margin | 49% | 54% | -500 bps |
| Operating Loss | ($7,446) | ($9,798) | $2,352 improvement |
| Net Loss | ($7,121) | ($13,000) | $5,879 improvement |
| Cash & Equivalents (End of Period) | $405 | $1,198 | ($793) / -66% |
| Working Capital | $639 | $1,365 | ($726) / -53% |
| Long-Term Debt | $134 | $137 | Minimal |
Note: Revenue is derived primarily from white-label manufacturing services and wellness products. The Infrastructure segment generated $164k in 2024 but $0 in 2025.
Material Changes and Operational Highlights
- Cost Reduction: Net loss decreased by approximately 45% ($5.9M) year-over-year, driven by a 35% reduction in Selling, General, and Administrative (SG&A) expenses ($4.4M vs $6.8M) due to headcount alignment and compensation restructuring.
- Segment Realignment: The Company exited the Infrastructure segment, which previously contributed revenue, to focus exclusively on Life Sciences and drug development.
- Asset Disposal: The Company impaired land in India by $3.3M in Fiscal 2024. In Fiscal 2025, this asset was classified as "held for sale" and subsequently sold for approximately $701k (Subsequent Event).
- Capital Raising: Raised approximately $4.64M in Fiscal 2025 through private placements and At-The-Market (ATM) offerings. A $12M credit facility with O-Bank remains available.
Guidance, Outlook, and Risks
Clinical Trial Progress (IGC-AD1)
- Phase 2 Interim Results: Positive interim data from the CALMA trial showed a statistically significant reduction in agitation (Cohen's d = 0.79, p=0.042) and sleep disturbances (78% reduction, p=0.02) compared to placebo.
- Safety Profile: No serious adverse events (SAEs) or deaths reported in the treatment arm to date.
- Outlook: The trial is ongoing with a target of 146 patients. Management anticipates additional data readouts in late 2025.
Strategic Initiatives
- AI Integration: Developing "MINT-AD," an AI-driven diagnostic platform for early Alzheimer's detection, and utilizing AI to optimize clinical trial protocols.
- Pipeline Expansion: Advancing preclinical candidates TGR-63 (amyloid-beta plaque disruption) and others targeting metabolic disorders.
Key Risks and Contingencies
- Liquidity: Cash balance of $405k is low relative to operating burn. The Company relies on the $12M credit facility and future equity raises to fund operations beyond 12 months.
- Regulatory: IGC-AD1 contains THC derived from hemp. While federally legal under the 2018 Farm Bill, the Company faces challenges in banking relationships and capital markets due to the "cannabis" classification.
- Development Risk: High failure rate in Alzheimer's drug development; no assurance that Phase 2 results will translate to Phase 3 success or FDA approval.
- Legal: Ongoing contractual dispute in Colombia (Engineering and Consulting Group SAS v. IGC Pharma) involving fraud allegations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $405k cash balance plus the $12M credit facility to fund the completion of the Phase 2 trial and subsequent Phase 3 planning without immediate dilutive equity raises.
- Clinical Data Validation: Review the full statistical analysis of the CALMA Phase 2 interim data, specifically the sample size (n=26 for interim) and the robustness of the placebo-controlled design.
- Regulatory Status: Confirm the FDA's stance on the hemp-derived THC formulation and any potential hurdles regarding the Investigational New Drug (IND) application.
- Debt Covenants: Examine the terms of the O-Bank credit facility for any financial covenants that could be triggered by continued losses or liquidity constraints.
- Asset Sale Completion: Confirm the final closing and net proceeds from the sale of the India land asset (reported as a subsequent event).